RxDoctor Payments Data

Zachary McCarty, OD

Optometrist · Chattanooga, TNNPI 1912011131

Payments from drug & device makers

$3,836in general payments, 2019–2025

Across 93 payments — averaging $41.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$888
  • Bausch & Lomb Americas Inc.$473
  • Johnson & Johnson Surgical Vision, Inc.$395
  • Coopervision Inc.$340
  • Glaukos Corporation$248
  • Mallinckrodt Hospital Products Inc.$202
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$3,79999%
  • Gifts$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,836 in reported general payments places this provider in the 85th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$119,828
Medicare patients
617
Services billed
1,438

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium34$11,999
CombiganBrimonidine Tartrate/Timolol20$8,117
LumiganBimatoprost22$7,934
RocklatanNetarsudil Mesylat/Latanoprost17$5,695
IlevroNepafenac15$5,403
SimbrinzaBrinzolamide/Brimonidine Tart19$3,795
Prednisolone Acetate128$3,584
MoxifloxacinMoxifloxacin Hcl85$2,711
Latanoprost296$2,518
Ketorolac Tromethamine48$1,033
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$822
Timolol Maleate81$776
Brimonidine Tartrate12$171
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim15$120

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCombigan, Lumigan$163$16,05142 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$100$11,99934 claims
Aerie Pharmaceuticals, Inc.Rocklatan$148$5,69517 claims
NovartisIlevro$43$5,40315 claims
AlconSimbrinza$888$3,79519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →